



Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

Ramesh K. Ramanathan¹ · Daniel D. Von Hoff¹ · Ferry Eskens² · George Blumenschein Jr.³ · Donald Richards⁴ · Isabelle Genvresse⁵ · Susanne Reschke⁵ · Camille Granvil⁶ · Adam Skubala⁷ · Carol Peña⁶ · Klaus Mross⁸

Published online: 27 October 2020
© The Author(s) 2020

Correction to: Targeted Oncology (2020) 15:163–174
<https://doi.org/10.1007/s11523-020-00714-0>

The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer, written by Ramesh K. Ramanathan, Daniel D. Von Hoff, Ferry Eskens, George Blumenschein Jr., Donald Richards, Isabelle Genvresse, Susanne Reschke, Camille Granvil, Adam Skubala, Carol Peña & Klaus Mross, was originally published Online First without Open Access. After publication in volume 15, issue 2, pages 163–174 the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to

© The Author(s) 2020 and the article is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <https://creativecommons.org/licenses/by-nc/4.0/>.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s11523-020-00714-0>.

✉ Daniel D. Von Hoff
dvh@tgen.org

¹ Virginia G. Piper Cancer Center/TGen, Scottsdale, AZ 85004, USA

² Erasmus MC Cancer Institute, PO Box 2040, 3015 GD Rotterdam, The Netherlands

³ The University of Texas MD Anderson Cancer Center, Unit 432, PO Box 301402, Houston, TX, USA

⁴ US Oncology Research, Texas Oncology, 910 E. Houston St., Suite 100, Tyler, TX 75702, USA

⁵ Pharmaceutical Division, Bayer AG, Müllerstraße 178, 13353 Berlin, Germany

⁶ Bayer HealthCare Pharmaceuticals, Inc, 100 Bayer Blvd, Whippany, NJ 07981, USA

⁷ Chrestos Concept GmbH & Co. KG, Girardetstr. 1-5, 45131 Essen, Germany

⁸ KTB Klinik für Tumorbiologie, Breisacher Str. 117, 79106 Freiburg Im Breisgau, Baden-Württemberg, Germany

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.